Sarfez Pharmaceuticals
Manufacturing · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8000 Towers Crescent Dr Ste 1388, Vienna...Phone Number
(703) 627-1934Website
www.sarfezpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Sarfez Pharmaceuticals
Sarfez Pharmaceuticals specializes in the development of torsemide-based diuretic therapies aimed at treating edema associated with heart failure and kidney disease. Their flagship product, SOAANZ, offers a slow-release formulation that promotes sustained diuresis over a duration of 6-8 hours. The company targets healthcare providers and patients seeking effective solutions for managing fluid retention and related conditions. Through innovation and advanced formulations, Sarfez Pharmaceuticals is dedicated to improving patient care in this therapeutic area.Explore more
Sarfez Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sarfez Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Sarfez Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Sarfez Pharmaceuticals
Check out if Sarfez Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Sarfez Pharmaceuticals has new funding data
Sarfez Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sarfez Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sarfez Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Sarfez Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Sarfez Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Sarfez Pharmaceuticals
Compare insights from companies similar to Sarfez Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sarfez Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sarfez Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sarfez Pharmaceuticals.
Sarfez Pharmaceuticals Tech Stack
A closer look at the technologies used by Sarfez Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Sarfez Pharmaceuticals News & Media
FDA Approves SOAANZ for Edema Treatment in Patients with Heart Failure and Renal Disease
Soaanz offers an alternative treatment for heart failure patients with edema who skip a loop diuretic dose due to concerns with excessive urination, as well as patients with chronic kidney disease. Loop diuretics are the drugs of choice for the treatment of volume overload caused by heart failure and chronic kidney disease. Soaanz is an oral once-a-day tablet with an extended duration of peak effect and with a longer time to achieve peak effect withoutSarfez Completes Formulation Development, Plans Clinical Trials for Combination of Loop Diuretic and SGLT-2 Inhibitor
USPTO Issues ‘Notice of Allowance’ for Company’s Patent Application, Boosts Development of New Treatments for Patients with Heart Failure (PRWeb September 26, 2019) Read the full story at https://www.prweb.com/releases/sarfez_completes_formulation_development_plans_clinical_trials_for_combination_of_loop_diuretic_and_sglt_2_inhibitor/prweb16595036.htmFDA to Review Sarfez Pharmaceuticals' Long-Acting Loop Diuretic 'SOANZXR': An Improved Treatment for Edema in Patients with Heart Failure, Kidney Disease and Hypertension
If approved, SoanzXRTM will be the first and only long acting loop diuretic (water pill) that delivers the drug at a slower rate and provides drug effects for the majority of the day with a single dose. Since SoanzXR releases drug at a slower rate and over a longer duration, and it induces gradual and sustained urination, it may help in reducing urinary incontinence, especially in older women. (PRWeb July 09, 2019) Read the full
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sarfez Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Sarfez Pharmaceuticals specializes in the development of torsemide-based diuretic therapies aimed at treating edema associated with heart failure and kidney disease. Their flagship product, SOAANZ, offers a slow-release formulation that promotes sustained diuresis over a duration of 6-8 hours. The company targets healthcare providers and patients s... Read More
